Gilead Sciences SWOT and PESTLE Analysis
COMPANY PROFILE -Gilead Sciences
Business Sector :Pharmaceutics and Biotechnology
Operating Geography :United States, North America, Global
About Gilead Sciences :
Gilead Sciences, Inc. is an American biopharmaceutical company that focuses primarily on antiviral drugs used in the treatment of Hepatitis B, Hepatitis C, HIV and influenza, including Sovaldi and Harvoni. It is headquartered at Foster City, California, United States. It was founded in June 1987 by Michael L. Riordan with the help of three core scientific advisers, Peter Dervan (Caltech), Doug Melton (Harvard) and Harold M. Weintraub (Fred Hutchinson Cancer Research Centre). The company has expanded to multiple drug segments through a series of strategic acquisitions starting from NeXstar Pharmaceuticals, Corus Pharma Inc. (2006), Raylo Chemicals Inc. (2006), CV Therapeutics (2009), CGI Pharmaceuticals (2010). The company’s product portfolio includes more than 25 products including complete treatment regiments for HIV and Hepatitis C virus. Gilead was ‘2021 Facility of the Year Awards’ winner for operational agility: COVID-19 impact. In August 2022, Gilead Sciences and MiroBio, a privately held biotechnology company based in the United Kingdom, signed a definitive deal under which Gilead will purchase MiroBio for about $405 million in cash. MiroBio's exclusive discovery technology and comprehensive portfolio of immune inhibitory receptor agonists will be acquired by Gilead. As of 2023, Gilead has commercial sales operations in the US and globally, with subsidiaries in 35+ countries. Gilead's global workforce of over 16,000 employees across six continents is dedicated to improving global healthcare and fostering a better, healthier world.
The USP of Gilead Sciences lies in it being the market leader for HIV drugs globally. Gilead Sciences mission statement reads “To discover, develop and commercialize innovative therapeutics in the areas of unmet medical needs that improve patient care.” The research based; biopharmaceutical company’s vision is “To advance therapeutics against life-threatening diseases worldwide.”
Gilead Sciences Revenue :
US$27.2 billion – FY ending 31st December 2022 (y-o-y decline of 0.09%)
US$27.3 billion – FY ending 31st December 2021 (y-o-y growth of 11%)
US$24.6 billion - FY ending 31st December 2020
Competitive Analysis of Gilead Sciences
1. Strong Brand Portfolio 2. Research and Development Orientation 3. Investments in process automation 4. Strategic Acquisitions and mergers | 1. Inability to accurately predict demand 2. Declining product sales in HIV and HCV segment 3. Reliance on three wholesalers for marketing and distribution |
1. High growth potential of the biopharmaceutical industry 2. Usage of Industry 4.0 technology 3. Expansion of footprint in various regions 4. Acquires XinThera to enhance oncology and inflammation pipeline 5. Expands collaboration for inflammatory disease therapies | 1. Certain challenges related to patent protection 2. Regulation of manufacturing process 3. Complexity of biopharma supply chain and operations 4. High competition in the industry 5. Rising cases of counterfeit products 6. AIDS advocates pressure company over drug pricing |
Complete Report
USD 12.53
- Debit/Credit card
- PayPal

Detailed SWOT Analysis of Gilead Sciences
Strength
1. Strong brand portfolio with high success: Gilead Sciences Inc. is considered to be the market leader in the treatment for HIV as per the reports. The company has a sizeable portfolio of HIV drugs like Viread, Stribild, Truvada, Atripla and Complera, Eviplera in Europe. These drugs are named as antiretroviral medicines, as it is formed by a combination of three or more drugs. Most of these drugs in the company’s portfolio for HIV drugs is based on Viread, however, the company is also involved in developing HIV drugs based on another compound called, tenefovir alafenamide with an improved safety profile. This will protect the company’s market due to erosion of Viread. The company is also leading in manufacturing drugs for Hepatitis C (HCV) patients. The American pharma giant had launched the drugs Sovaldi and Harvoni in 2013 and 2014 respectively. These were an immediate success in the market and helped the company in boosting its profitability. In addition to these segments, its portfolio also includes cardiovascular drugs, drugs for liver diseases, oncology drugs, respiratory and inflammatory drugs. Its portfolio also includes treatment for Covid-19, which was approved in 2021. As of 2023, Gilead has commercial sales operations in the US and globally, with subsidiaries in 35+ countries. Its products are marketed through commercial teams and third-party distributors.
2. Deep roots in Research and Development: Gilead Sciences, Inc. is a research-based company which discovers, develops and commercializes in understanding and catering to unmet medical needs. It won Food and Drug Administration (FDA) approval for HIV drug, Biktarvy, on February 7, 2018. Its product Yescarta was named as co-winner of the 2018 Prix Gallen USA Award for the best biotechnology product. A few of the advantages of this new drug includes its minimal drug to drug interactions and no black warning for liver toxicity. This drug is touted as the biggest product launch of 2018. In 2022, Yescarta® (axicabtagene ciloleucel) CAR T-cell treatment was approved by the US Food and Drug Administration (FDA) for adult patients with large B-cell lymphoma who are refractory to first-line chemoimmunotherapy or who relapse within 12 months after first-line chemoimmunotherapy. FDA also approved Veklury® (remdesivir), which is used to treat adult and adolescent patients who are not hospitalised but are at a high risk of developing severe COVID-19, which could result in hospitalisation or death.
The company has also entered into many partnerships, licensing, mergers & acquisitions or equity investment deals from few years to enhance its research pipeline in therapeutic areas including HIV, oncology, immunotherapy, inflammation and liver disease. These include collaborations with Pfizer, Sangamo Therapeutics, verily to name a few. Gilead Sciences has focused on enhancing its commercial portfolio and clinical pipeline through acquisitions, collaborations, and in-licensing. In 2022, they announced collaborations with Dragonfly Therapeutics, Arcellx, and MacroGenics, as well as the acquisitions of MiroBio, Tmunity Therapeutics, and rights to GS-1811. These initiatives aim to drive transformative science, build a sustainable portfolio, and ensure long-term growth. Gilead Sciences experienced an increase of $376 million in research and development expenses.
The remaining section under "Strength" is available only in the 'Complete Report' on purchase.
Weakness
This section is available only in the 'Complete Report' on purchase.
Opportunity
This section is available only in the 'Complete Report' on purchase.
Threat
This section is available only in the 'Complete Report' on purchase.
Complete Report
USD 12.53
- Debit/Credit card
- PayPal

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?



You may also be interested in other analyses of Gilead Sciences:
-
Gilead Sciences Porter's Five Forces Analysis -
Gilead Sciences VRIO Analysis -
Gilead Sciences Value Chain Analysis -
Gilead Sciences Covid-19 Impact Analysis -
Gilead Sciences BCG Analysis -
Gilead Sciences Segmentation, Targeting and Positioning (STP) Analysis -
Gilead Sciences Ansoff Matrix Analysis


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.


Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Check Out Analysis of Other Relevant Companies
References used in Gilead Sciences SWOT & PESTLE Analysis Report
1. Gilead Sciences annual report 2022 - https://www.annualreports.com/HostedData/AnnualReports/PDF/NASDAQ_GILD_2022.pdf
2. Gilead Sciences company website - https://www.gilead.com/
3. Gilead Sciences company profile - https://money.cnn.com/quote/profile/profile.html?symb=GILD
4. 5 Drugs That Are Critical for Gilead Sciences' Future - https://www.fool.com/investing/2018/02/22/5-drugs-that-are-critical-for-gilead-sciences-futu.aspx
The detailed complete set of references are available on request in the 'Complete report' on purchase.
How to Reference This Page?
You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.
Gilead Sciences SWOT and PESTLE Analysis - SWOT & PESTLE.COM
SWOT & PESTLE.com (2025). Gilead Sciences SWOT and PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/gilead-sciences/ [Accessed 14 Feb, 2025].
In-text: (SWOT & PESTLE.com, 2025)
Copyrights and Disclaimer
Gilead Sciences SWOT and PESTLE analysis has been conducted by Pallavi Roy and reviewed by senior analysts from Barakaat Consulting.
Copyright of Gilead Sciences SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.